window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Central Nervous System

  • Biotech & Pharma Business,Central Nervous System,Drug Discovery & Development

    Deep Science Ventures and Medicines Discovery Catapult target blood-brain barrier challenge

    Deep Science Ventures and Medicines Discovery Catapult have launched a [...]

    June 6, 2026
  • Central Nervous System,Digital & Data,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Bonito Biosciences partners with DaltonTx on AI-driven RNA delivery research

    Bonito Biosciences has entered a collaboration with DaltonTx to develop [...]

    June 6, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    May 5, 2026
  • Central Nervous System,Drug Discovery & Development,Therapeutic Areas

    Strategies to extend ketamine antidepressant effects identified in new study

    Researchers have identified a molecular target that could extend the [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    International Brain Health Conference 2026 to focus on early intervention before dementia

    The inaugural International Brain Health Conference 2026 in Edinburgh will [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia

    Newron Pharmaceuticals has secured up to EUR 38 million in [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Insilico Medicine and CMS announce AI-powered drug discovery collaborations in CNS and autoimmune diseases

    Insilico Medicine and China Medical System Holdings Limited (CMS) have [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oryzon appoints Rolando Gutierrez-Esteinou as chief medical officer for CNS programs

    Oryzon Genomics has appointed Rolando Gutierrez-Esteinou, as chief medical officer [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Alto Neuroscience completes Phase 2 enrollment for ALTO-101 in cognitive impairment associated with schizophrenia

    Alto Neuroscience has completed patient enrollment in its Phase 2 [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Skyhawk reports encouraging 12-month Huntington’s disease data for SKY-0515
    Categories: Advanced Therapies, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • NICE backs serplulimab for extensive-stage small cell lung cancer
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Quotient Sciences begins Phase 1 study of AI-designed drug formulation
    Categories: Clinical & Regulatory, Digital & Data, Drug Discovery & Development, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top